IMW 2021 | MRD’s place in decision making
Lanny Kirsch
• 9 Sep 2021
Lanny Kirsch, MD, Adaptive Biotechnologies, Seattle, WA, talks on the role of measurable residual disease (MRD) in decision-making for treatment of multiple myeloma. Dr Kirsch explains that MRD is only one component which is used to inform decisions and taken together with disease symptoms, quality of life issues, stage of therapy and more, MRD is a valuable asset to ensure the most appropriate steps in treatment are taken. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
Disclosures
Lanny Kirsch, MD, is an employee and stock option holder in Adaptive Biotechnologies, Inc.
